CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2047-783X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer ; volume:27 ; number:1 ; day:2 ; month:7 ; year:2022 ; pages:1-13 ; date:12.2022
European journal of medical research ; 27, Heft 1 (2.7.2022), 1-13, 12.2022

Creator
Chen, Xi
Wu, Yechen
Wang, Xinan
Xu, Chengdang
Wang, Licheng
Jian, Jingang
Wu, Denglong
Wu, Gang
Contributor
SpringerLink (Online service)

DOI
10.1186/s40001-022-00730-y
URN
urn:nbn:de:101:1-2022082219074858559302
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Chen, Xi
  • Wu, Yechen
  • Wang, Xinan
  • Xu, Chengdang
  • Wang, Licheng
  • Jian, Jingang
  • Wu, Denglong
  • Wu, Gang
  • SpringerLink (Online service)

Other Objects (12)

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

Related objects